These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22960736)

  • 21. [Issues in therapeutic drug monitoring evaluation].
    Paintaud G; Le Guellec C; Furet Y; Autret-Leca E
    Therapie; 2001; 56(3):245-9. PubMed ID: 11475802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whither therapeutic drug monitoring?
    Doogue MP; Martin JH
    Intern Med J; 2010 Oct; 40(10):671-2. PubMed ID: 20958899
    [No Abstract]   [Full Text] [Related]  

  • 23. Individualized dosing with anesthetic agents.
    Lemmens HJ; Stanski DR
    Clin Pharmacol Ther; 2012 Oct; 92(4):417-9. PubMed ID: 22992669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
    Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
    Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety.
    Haen E
    Pharmacopsychiatry; 2011 Sep; 44(6):254-8. PubMed ID: 21959787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations.
    Rogers HL; Bhattaram A; Zineh I; Gobburu J; Mathis M; Laughren TP; Pacanowski M
    J Clin Psychiatry; 2012 Sep; 73(9):1187-90. PubMed ID: 23059146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug dosing adjustments in patients with chronic kidney disease.
    Munar MY; Singh H
    Am Fam Physician; 2007 May; 75(10):1487-96. PubMed ID: 17555141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
    Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
    Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perils of polypharmacy: 10 steps to prudent prescribing.
    Carlson JE
    Geriatrics; 1996 Jul; 51(7):26-30, 35. PubMed ID: 8675045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics and personalized medicine.
    Li-Wan-Po A
    J Clin Pharm Ther; 2012 Dec; 37(6):617-9. PubMed ID: 23013532
    [No Abstract]   [Full Text] [Related]  

  • 31. Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring.
    Takada M; Goto T; Kotake T; Saito M; Kawato N; Nakai M; Gunji T; Shibakawa M
    J Clin Pharm Ther; 2005 Feb; 30(1):5-12. PubMed ID: 15658999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Posology and therapeutic follow-up of drugs].
    Soins; 1998 Sep; (628):57-8. PubMed ID: 9823268
    [No Abstract]   [Full Text] [Related]  

  • 33. Dosing nomograms: silos on a slope.
    Dager WE
    Ann Pharmacother; 2009 Jan; 43(1):114-7. PubMed ID: 19126822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic drug monitoring with the help of serum concentration measurements. How are the analytic results distributed in a population?].
    Skomedal T; Osnes JB; Johannessen SI; Lund PK; Aass H
    Tidsskr Nor Laegeforen; 1993 Aug; 113(18):2242-6. PubMed ID: 8362387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a low order drug-cell response surface for applications in personalized medicine.
    Ding X; Liu W; Weiss A; Li Y; Wong I; Griffioen AW; van den Bergh H; Xu H; Nowak-Sliwinska P; Ho CM
    Phys Biol; 2014 Nov; 11(6):065003. PubMed ID: 25427213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Educational and organizational interventions to improve the usefulness of clinical pharmacological advice for personalized drug dosing based on therapeutic drug monitoring.
    Pea F; Dose L; Cojutti P; Baraldo M; Fontana F; Favaretti C; Furlanut M
    Basic Clin Pharmacol Toxicol; 2014 Nov; 115(5):432-7. PubMed ID: 24703163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Finding the maximum safe dose level for heteroscedastic data.
    Tamhane AC; Logan BR
    J Biopharm Stat; 2004 Nov; 14(4):843-56. PubMed ID: 15587967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease.
    Hassan Y; Al-Ramahi RJ; Aziz NA; Ghazali R
    Ann Pharmacother; 2009 Oct; 43(10):1598-605. PubMed ID: 19776297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations.
    Barras MA; Duffull SB; Atherton JJ; Green B
    Ther Drug Monit; 2010 Aug; 32(4):482-8. PubMed ID: 20592650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Individualization of drug dosage by therapeutic monitoring in plasma and the application of pharmacokinetic principles].
    Klotz U
    J Clin Chem Clin Biochem; 1983 Nov; 21(11):649-58. PubMed ID: 6655441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.